Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naltrexone + methylphenidate
- Development stage
- Unknown
- Lead developer
- Avekshan
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Naltrexone + methylphenidate is an investigational drug combination consisting of naltrexone, an opioid receptor antagonist, and methylphenidate, a central nervous system stimulant. The combination is evaluated primarily for the treatment of attention-deficit/hyperactivity disorder (ADHD). Naltrexone blocks μ-opioid receptors, reducing the euphoric effects and potentially the abuse liability of methylphenidate, while methylphenidate acts as a stimulant to improve ADHD symptoms. Clinical studies found the combination did not interfere with the clinical efficacy of methylphenidate for ADHD and showed no increase in adverse events, and also attenuated stimulant-induced euphoria in adults with ADHD[1][3][5][6].
- Brand names
- naltrexone + methylphenidate
- Other names
- naltrexone + methylphenidate
02
Targets
MOR (Mu opioid receptor)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on naltrexone + methylphenidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naltrexone + methylphenidate.